The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting drug it has developed to create a new standard of patient care for weight ...

Following the release of upbeat data and given some recent signs of stabilization in the stocks, MarketWatch took at look at companies in the healthcare sector that are expected to produce the fastest ...

New dementia diagnoses have significantly decreased since 2015, a study published in BMJ found.But more people are living ...

TD Cowen has lowered Eli Lilly’s price target from $1,050 to $960, but maintained a Buy rating, citing solid long-term ...

This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Weber, a New York Times bestselling author and ordained Lutheran pastor, will speak in Staples Auditorium on the campus of ...

Erste Group has downgraded Eli Lilly from a buy to a hold rating due to concerns about its earnings forecast. Despite 36.38% ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

This was the stock's fifth consecutive day of gains.

Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...